Table of Contents Table of Contents
Previous Page  99 / 812 Next Page
Information
Show Menu
Previous Page 99 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S72–S115

S95

against glutaminergic excitotoxicity in patients with OCD. Further

studies including patients with other psychiatric illnesses as con-

trols are required for confirmation of the above findings.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.059

Psychopharmacology and pharmacoeconomics

FC56

Impact of DRD2 polymorphisms on

prolactin level in risperidone-treated

Thai children and adolescent with

autism spectrum disorders

C. Sukasem

, Y. Hongkaew

Faculty of Medicine Ramathibodi hospital, Pathology, Bangkok,

Thailand

Corresponding author.

Introduction

A large number of studies have reported that the

prolactin concentration was significantly increased in the Taq1A

A1 allele carriers because several reports revealed that individuals

with the DRD2 Taq1A A1 allele have a reduced density of brain D2

receptors.

Objective

The main aim of this study was to identify the impact

of pharmacogenetic markers associated with prolactin concentra-

tion in risperidone-treated children and adolescents with autism

spectrum disorders.

Methods

One hundred and forty-seven children and adolescents

with autism, aged 3 to 19, received risperidone. The clinical data of

patients were recorded frommedical records. Prolactin levels were

measured by chemiluminescence immunoassay. Three

CYP2D6

sin-

gle nucleotide polymorphisms (SNPs), CYP2D6*

4

(1846G>A), *

1

0

(100C>T), and *

41

(2988G>A), one gene deletion (*

5

), and

DRD2

Taq1A

(rs1800497) polymorphism were genotyped by TaqMan

real-time PCR.

Results

The three common allelic frequencies were CYP2D6*

10

(55.10%), *

1

(32.65%) and *

5

(6.12%), respectively. Patients were

grouped according to their

CYP2D6

genotypes. The

DRD2

geno-

type frequencies were

Taq1A

A2A2 (38.77%), A1A2 (41.50%), and

A1A1 (19.73%), respectively. There were statistically significant

differences in prolactin level of patients among the three groups

(

P

= 0.033). The median prolactin level in patients with

DRD2

Taq1A

A2A2 (17.80 ng/mL) was significantly higher than A1A2

(17.10 ng/mL) and A1A1 (12.70 ng/mL).

Conclusion DRD2 Taq1A

A2A2 polymorphisms may be a critical

role in an influence prolactin elevation during risperidone treat-

ment in ASD.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.060

FC57

Detection of CYP2D6 polymorphism

using Luminex xTAG technology in

autism spectrum disorder: CYP2D6

activity score and its association with

risperidone levels

C. Sukasem

, S. Santon

Faculty of Medicine Ramathibodi hospital, Pathology, Bangkok,

Thailand

Corresponding author.

Introduction

The determination of the accurate

CYP2D6

genotyp-

ing is essential in the clinical setting and individualization of drug

therapy.

Objectives

In this study, was to apply the Luminex xTAG tech-

nology to detect significant

CYP2D6

polymorphisms and copy

number variation, including assessment the relationship of

CYP2D6

polymorphisms and risperidone plasma concentration in autism

spectrum disorder children (ASD) treated with risperidone.

Methods

All 84 ASD patients included in this study had been

receiving risperidone at least for 1 month. The

CYP2D6

geno-

types were determined by luminex assay. Plasma concentrations

of risperidone and 9-hydroxyrisperidone were measured using

LC/MS/MS.

Results

Among the 84 patients, the most common genotype was

CYP2D6*1/*10

(26.19%). The most common allele was

CYP2D6*10

(51.79%) and the second most allele was

CYP2D6*1

(27.98%).

There were 46 (55.42%) classified as EM, 33 (39.76%) as IM, and

4 (4.82%) as UM. The plasma concentration of risperidone and

risperidone/9-hydroxyrisperidone ratio in the patients were sig-

nificant differences among the CYP2D6 predicted phenotype group

(

P

= 0.001 and

P

< 0.0001, respectively). Moreover, the plasma con-

centration of risperidone and risperidone/9-hydroxyrisperidone

ratio in the patients with CYP2D6 activity score 0.5 were sig-

nificantly higher than those with the CYP2D6 activity score 2.0

(

P

= 0.004 and

P

= 0.002, respectively).

Discussions

The present study suggests that it would be ideal to

identify the

CYP2D6

genotype of patients before prescribing and

administering risperidone. Furthermore, the use of

CYP2D6

gene

scoring system to determine an individual’s metabolic capacity

may become an essential tool for a more rational and safer drug

administration.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.061

FC58

Angiotensin II type 1 receptor

blockade diminishes negative effect of

chronic stress on memory via

upregulation of brain-derived

neurotrophic factor

D. Wincewicz

1 ,

, A. Juchniewicz

2

1

Medical University of Bialystok, Department of Clinical

Pharmacology, Bialystok, Poland

2

Medical University of Bialystok, Department of Clinical Molecular

Biology, Bialystok, Poland

Corresponding author.

Introduction

A critical need exists for progress in the char-

acterization of targets for pro-cognitive drug discovery. We

previously demonstrated that Telmisartan (TLM), an angiotensin

type 1 receptor (AT1) blocker and partial agonist of peroxi-

some proliferator-activated receptor gamma (PPAR ), alleviates

cognitive decline in chronically stressed rats. Understanding of

mechanistic background of this phenomenon is hampered by both

dual binding sites of TLM and limited data on the molecular conse-

quences of central AT1 blockade and PPAR activation.

Objectives

To discriminate molecular effects of AT1 blockade and

PPAR activation in stress induced memory impairment.

Aims

In this study, we investigated mechanism of neuroprotec-

tion provided by TLM in chronic psychological stress.

Methods

We analyzed BDNF gene expression in the hippocam-

pus (HIP) and medial prefrontal cortex (mPFC) in chronically

restrained stressed Wistar rats (2.5 h, 21 days), repeatedly treated

with TLM (1mg/kg), GW9662 (0.5mg/kg) – a selective PPAR

receptor antagonist, or both in combination. TATA box binding pro-

tein (Tbp) was an internal control for expression studies.